Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 9/20 | 0.47 |
| ▸ | PAK1 | Q13153 | 7/20 | 0.47 |
| ▸ | JAK2 | O60674 | 3/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 6/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14633693 | 0.82 | EPHB4 (0.48) | EPHB4PAK1KDRCYP3A4CYP2C9 | |
| SCHEMBL14633736 | 0.81 | EPHB4 (0.61) | EPHB4KDRCYP3A4CYP2C9PDGFRB | |
| SCHEMBL2436346 | 0.80 | EPHB4 (0.46) | EPHB4PAK1KDRCYP3A4CYP2C9 | |
| SCHEMBL14633924 | 0.79 | ABCB11 (0.41) | EPHB4PAK1JAK2JAK3KDR | |
| SCHEMBL14633596 | 0.77 | PIK3CA (0.33) | — | |
| SCHEMBL14634052 | 0.76 | ABCB11 (0.54) | EPHB4PAK1JAK2JAK3KDR | |
| SCHEMBL14634185 | 0.76 | EPHB4 (0.49) | EPHB4PAK1JAK2JAK3KDR | |
| SCHEMBL14634130 | 0.75 | KDR (0.60) | EPHB4KDRCYP3A4CYP2C9CYP2D6 | |
| SCHEMBL14633593 | 0.74 | ABCB11 (0.39) | EPHB4PAK1JAK2JAK3KDR | |
| SCHEMBL14633998 | 0.73 | EPHB4 (0.46) | EPHB4PAK1JAK2JAK3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | MAP3K19, MAP3K1, MAP3K20 | EPHB4 2462/4885PAK1 287/4885JAK2 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.